Solid Biosciences (SLDB) Earnings Analysis

Solid Biosciences (SLDB) next reports earnings on 2026-08-11, consensus EPS -0.43 USD. Last quarter (2026-03-19) it beat with EPS -0.5 USD vs -0.51 USD est (+2%). It has beaten estimates in 2/5 recent quarters (40%). Trailing P/E -4.15.

Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades

When does SLDB next report earnings?

Next earnings date2026-08-11
Consensus EPS estimate-0.43 USD
Revenue estimaten/a

SLDB earnings history — beats and misses

Quarter (report date)EPS actualEPS est.SurpriseResult
2026-03-19-0.5 USD-0.51 USD+2%Beat
2025-11-03-0.48 USD-0.42 USD-14.3%Miss
2025-08-12-0.42 USD-0.51 USD+17.6%Beat
2025-05-15-0.59 USD-0.53 USD-11.3%Miss
2025-03-06-0.89 USD-0.79 USD-12.7%Miss

Beat rate: 2/5 (40%) over reported quarters with consensus data.

SLDB valuation and analyst view

Trailing P/E-4.15
Trailing EPS-1.74645 USD
Price / book2.38
Dividend yield0.00%
Market cap0.63B
Analyst consensusBuy (16 buy / 5 hold / 0 sell)
Avg price target17 USD

Related research pages

Frequently asked questions

When is Solid Biosciences (SLDB)'s next earnings date?

Solid Biosciences is next scheduled to report on 2026-08-11, with a consensus EPS estimate of -0.43 USD.

Did SLDB beat earnings last quarter?

In its 2026-03-19 report, SLDB posted EPS of -0.5 USD versus a -0.51 USD estimate — a beat of 2%.

What is SLDB's earnings track record?

Over the last 5 reported quarters with consensus data, SLDB beat estimates 2 times (40%).

What is SLDB's current P/E ratio and EPS?

SLDB trades at a trailing P/E of -4.15 on trailing EPS of -1.7464479413492187 USD.

What do analysts rate SLDB?

Analyst consensus is "Buy" across 21 ratings (0 strong buy, 16 buy, 5 hold, 0 sell, 0 strong sell). Average 12-month price target: 17 USD.